Comparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria

Table 2 Positive results of serology, in-house mPCR, and commercial PCR classified by atypical bacteria

Techniques	Group 1^a NPS	Group 2^b NPA	Group 3^c NPS and IS	Group 4^d NPS
M. pneumoniae	n (%)	n (%)	n (%)	n (%)
Serology	5/46 (10.9)	4/77 (5.2)	21/48 (43.8)	2/19 (10.5)
mPCR	1/68 (1.5)	0/88 (0)	NPS: 7 (14.3) IS: 18 (36.7)	0/20 (0)
Commercial PCR [Trade mark]	4/68 (5.9) [Speed-oligo]	1/88 (1.4) [Speed-oligo]	13/49 (26.5) [Seeplex]	0/20 (0) [Speed-oligo]
C. pneumoniae
Serology	3/46 (6.5)	9/77 (11.7)	6/48 (12.5)	4/19 (21.1)
mPCR	0/68 (0)	0/88 (0)	NPS: 0 (0) IS: 0 (0)	0/20 (0)
Commercial PCR	0/68 (0)	1/88 (1.4)	0/49 (0)	0/20 (0)
L. pneumophila
Serology	3/46 (6.5)	2/77 (2.6)	5/48 (10.4)	0/19 (0)
mPCR	0/68 (0)	0/88 (0)	NPS: 0 (0) IS: 0 (0)	1/20 (5.0)
Commercial PCR	2/68 (2.9)	0/88 (0)	0/49 (0)	4/20 (21)

NPS Nasopharyngeal swab, NPA Nasopharyngeal aspirate, IS Induced sputum
^aProspective adults with community-acquired pneumonia (CAP). Speed-Oligo® was run as commercial PCR on the NPSs
^bRetrospective adults with CAP. Speed-Oligo® was run as commercial PCR on the NPAs
^cChildren with CAP. Seeplex® PneumoBacter was run as a commercial PCR on IS
^dIndividuals without CAP. Speed-oligo® was run as a commercial PCR on NPSs

ISSN: 1477-5751